Summary
IMvigor010 was a phase 3 randomised controlled trial investigating adjuvant atezolizumab versus observation in patients with muscle-invasive urothelial carcinoma at high risk of recurrence following radical cystectomy. As suggested by the title and journal context (2021), the trial assessed whether checkpoint inhibitor therapy could improve disease-free and overall survival outcomes in this patient population. The study involved multiple international centres and represents clinical evidence on immunotherapy efficacy in the adjuvant setting for this malignancy.
UK applicability
The findings from this multicentre international trial are directly relevant to UK oncology practice and NHS Cancer Drugs Fund considerations for adjuvant urothelial cancer treatment. Results would inform NICE appraisals and treatment pathways for muscle-invasive bladder cancer in the United Kingdom.
Key measures
Disease-free survival, overall survival, recurrence-free interval, adverse events
Outcomes reported
The study evaluated disease-free survival and overall survival outcomes in patients with muscle-invasive urothelial carcinoma receiving adjuvant atezolizumab (an anti-PD-L1 immunotherapy) versus observation following radical cystectomy.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.